Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced encouraging topline results from its Phase 2b SEISMiC Extension Study investigating istaroxime in patients experiencing early cardiogenic shock due to heart …
Windtree Therapeutics Announces Positive Results in Heart Failure Study Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made strides in the fight against neurodegenerative diseases with the filing of three new patents. These cover novel combination therapies involving their …
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has revealed promising patient-reported outcomes showing that Rezdiffra (resmetirom) significantly enhances health-related quality of life (HRQL) for individuals with nonalcoholic steatohepatitis (NASH) with …
Madrigal Pharmaceuticals Announces Positive Quality of Life Outcomes for Rezdiffra in NASH Treatment Read More
NEWTOWN, PA — Helius Medical Technologies, Inc. (Nasdaq:HSDT) has announced promising preliminary findings from its PoNSTEP study, which evaluates the impact of adherence to the Portable Neuromodulation Stimulator (PoNS®) Therapy on …
Helius Medical Technologies Reports Positive Preliminary Results from PoNSTEP Study Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has reported encouraging topline results from its Phase 1 trial of ratutrelvir, an oral inhibitor designed to combat COVID-19. The trial demonstrated favorable …
Promising Phase 1 Results for Traws Pharma’s COVID Treatment Candidate Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported promising outcomes from its Phase 2b SEISMiC Extension Study, showcasing the potential of istaroxime in managing early cardiogenic shock caused by …
Windtree Therapeutics Announces Promising Results for Heart Failure Drug Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a significant milestone in its Advance-HTN trial by hitting its enrollment target of 261 participants. This pivotal trial is crucial in …
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial Read More
MALVERN, PA — YPrime has been recognized as a Trailblazer in the Everest Group’s Clinical Trial Patient Engagement Products Assessment. This accolade highlights YPrime’s dedication to enhancing patient participation and engagement …
YPrime Honored as Trailblazer in Clinical Trial Patient Engagement Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently unveiled a draft guidance designed to enhance multiregional clinical trials (MRCTs) in oncology, aimed at improving data relevance for …
FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to …
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis Read More